Company News
AbbVie Gets Positive EU Opinion on Vitiligo
AbbVie received a positive opinion from EMA's CHMP for upadacitinib 15 mg once daily for adult and adolescent non‑segmental vitiligo.
The opinion is based on two Phase 3 trials where upadacitinib met
